First Quarter Report 2014
Please find enclosed the report for the 1st quarter 2014.
Highlights for first quarter 2014:
Nordic Nanovector’s first lead product candidate Betalutin™ has achieved the two major objectives from the phase I portion of the ongoing phase I/II clinical trial. The ongoing trial has demonstrated that Betalutin™ is safe and well tolerated in patients suffering from Non-Hodgkin Lymphoma and that the product has a clinically relevant effect in this patient population. The positive results from Phase I has enabled the company to establish the dose interval for the Phase II part of the clinical trial, which will assess the efficacy of Betalutin™ in patients suffering from relapsed Non-Hodgkin Lymphoma.
Nordic Nanovector is planning the financing of the further development of Betalutin™ for treatment of non-Hodgkin Lymphoma. The Company has for this purpose engaged ABG Sundal Collier and DNB Markets to explore the possibility of a pre-IPO financing. The Company is currently in the process of carrying out a sounding process towards a limited number of institutional investors. The outcome of the sounding process is expected during Q2 2014. No decision regarding a financing has been made at the current stage and the Company will update its shareholders if and when appropriate.
Jan A. Alfheim, CEO
Phone: ( 47) 22 18 33 01
Cell: ( 47) 46 44 00 45
Fax: ( 47) 22 58 00 07
E-mail: jaa@nordicnanovector.no
Tone Kvåle, CFO
Phone: ( 47) 22 18 33 01
Cell: ( 47) 91 51 95 76
Fax: ( 47) 22 58 00 07
E-mail: tkv@nordicnanovector.no
About Nordic Nanovector AS
Nordic Nanovector AS is a privately held company established in 2009. The company is based in Norway and has offices and laboratories in Oslo. The company is developing novel innovative anticancer radioimmunotherapeutics to treat Non-Hodgkin Lymphoma (NHL) and other hematological malignancies.
About Betalutin
Betalutin™, is a pharmaceutical product candidate consisting of a radionuclide conjugated to a tumor seeking carrier/antibody, which can be used for irradiation of malignant metastasized tumors with minimal damage to nearby healthy normal tissue. This technology aims to prolong and improve the quality of life of people who suffer from non-Hodgkin Lymphoma (NHL).
Tags:
